Share your opinion about this

5
Comment
Favorite

Share your opinion about this news…

GlaxoSmithKline Sues Pfizer and BioNTech Over Covid-19 Vaccine Technology

April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies

GlaxoSmithKline Sues Pfizer and BioNTech Over Covid-19 Vaccine Technology

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":299139941277968,"tweetId":"299139941277968","gmtCreate":1714058341531,"gmtModify":1714058920297,"author":{"id":3565129212543795,"idStr":"3565129212543795","authorId":3565129212543795,"authorIdStr":"3565129212543795","name":"Lianhou","avatar":"https://static.tigerbbs.com/334dbb3af8dbec25c618218b824ec51d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Share your opinion about this news…</p></body></html>","htmlText":"<html><head></head><body><p>Share your opinion about this news…</p></body></html>","text":"Share your opinion about this news…","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/299139941277968","repostId":2430285672,"repostType":2,"repost":{"id":"2430285672","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1714057800,"share":"https://www.laohu8.com/m/news/2430285672?lang=&edition=full","pubTime":"2024-04-25 23:10","market":"us","language":"en","title":"GlaxoSmithKline Sues Pfizer and BioNTech Over Covid-19 Vaccine Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2430285672","media":"Reuters","summary":"April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies","content":"<html><head></head><body><p>April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies&#39; blockbuster COVID-19 vaccines.</p><p>GSK said in the lawsuit that Pfizer and BioNTech&#39;s Comirnaty vaccines violate the company&#39;s patent rights in mRNA-vaccine innovations developed &#34;more than a decade before&#34; the outbreak of the COVID-19 pandemic.</p><p>A Pfizer spokesperson said in a statement that the company is &#34;confident in our IP position around Comirnaty&#34; and intends to &#34;vigorously defend&#34; against GSK&#39;s claims. A BioNTech spokesperson declined to comment on the complaint.</p><p>A GSK spokesperson said the company believes its patents &#34;provided the foundational technology used in Pfizer and BioNTech’s COVID-19 mRNA vaccines,&#34; and that it is &#34;willing to license these patents on commercially reasonable terms and to ensure continued patient access&#34; to the shots.</p><p>The lawsuit adds to a web of high-stakes U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their vaccines, including a case brought by Moderna against Pfizer in 2022.</p><p>Pfizer made $11.2 billion from sales of Comirnaty last year, while Moderna earned $6.7 billion in revenue from its vaccine Spikevax. Sales of both vaccines declined significantly last year from 2022.</p><p>London-based GSK asked the court for an unspecified amount of monetary damages from Pfizer and BioNTech that includes an ongoing patent-licensing fee.</p><p>GSK said in the complaint that its patents cover technology for transporting fragile mRNA into human cells that scientists began developing in 2008. GSK said it bought the rights to the inventions when it acquired part of Novartis&#39; NOVN.S vaccines business in 2015.</p><p>GSK also sued Pfizer for patent infringement last year over technology used in Pfizer&#39;s respiratory syncytial virus (RSV) vaccine Abrysvo. Pfizer has denied GSK&#39;s claims in that case.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GlaxoSmithKline Sues Pfizer and BioNTech Over Covid-19 Vaccine Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxoSmithKline Sues Pfizer and BioNTech Over Covid-19 Vaccine Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-04-25 23:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies&#39; blockbuster COVID-19 vaccines.</p><p>GSK said in the lawsuit that Pfizer and BioNTech&#39;s Comirnaty vaccines violate the company&#39;s patent rights in mRNA-vaccine innovations developed &#34;more than a decade before&#34; the outbreak of the COVID-19 pandemic.</p><p>A Pfizer spokesperson said in a statement that the company is &#34;confident in our IP position around Comirnaty&#34; and intends to &#34;vigorously defend&#34; against GSK&#39;s claims. A BioNTech spokesperson declined to comment on the complaint.</p><p>A GSK spokesperson said the company believes its patents &#34;provided the foundational technology used in Pfizer and BioNTech’s COVID-19 mRNA vaccines,&#34; and that it is &#34;willing to license these patents on commercially reasonable terms and to ensure continued patient access&#34; to the shots.</p><p>The lawsuit adds to a web of high-stakes U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their vaccines, including a case brought by Moderna against Pfizer in 2022.</p><p>Pfizer made $11.2 billion from sales of Comirnaty last year, while Moderna earned $6.7 billion in revenue from its vaccine Spikevax. Sales of both vaccines declined significantly last year from 2022.</p><p>London-based GSK asked the court for an unspecified amount of monetary damages from Pfizer and BioNTech that includes an ongoing patent-licensing fee.</p><p>GSK said in the complaint that its patents cover technology for transporting fragile mRNA into human cells that scientists began developing in 2008. GSK said it bought the rights to the inventions when it acquired part of Novartis&#39; NOVN.S vaccines business in 2015.</p><p>GSK also sued Pfizer for patent infringement last year over technology used in Pfizer&#39;s respiratory syncytial virus (RSV) vaccine Abrysvo. Pfizer has denied GSK&#39;s claims in that case.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4588":"碎股","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4568":"美国抗疫概念","PFE":"辉瑞","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BNTX":"BioNTech SE","GSK":"葛兰素史克","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4551":"寇图资本持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4581":"高盛持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4548":"巴美列捷福持仓","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4592":"伊斯兰概念","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2430285672","content_text":"April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed \"more than a decade before\" the outbreak of the COVID-19 pandemic.A Pfizer spokesperson said in a statement that the company is \"confident in our IP position around Comirnaty\" and intends to \"vigorously defend\" against GSK's claims. A BioNTech spokesperson declined to comment on the complaint.A GSK spokesperson said the company believes its patents \"provided the foundational technology used in Pfizer and BioNTech’s COVID-19 mRNA vaccines,\" and that it is \"willing to license these patents on commercially reasonable terms and to ensure continued patient access\" to the shots.The lawsuit adds to a web of high-stakes U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their vaccines, including a case brought by Moderna against Pfizer in 2022.Pfizer made $11.2 billion from sales of Comirnaty last year, while Moderna earned $6.7 billion in revenue from its vaccine Spikevax. Sales of both vaccines declined significantly last year from 2022.London-based GSK asked the court for an unspecified amount of monetary damages from Pfizer and BioNTech that includes an ongoing patent-licensing fee.GSK said in the complaint that its patents cover technology for transporting fragile mRNA into human cells that scientists began developing in 2008. GSK said it bought the rights to the inventions when it acquired part of Novartis' NOVN.S vaccines business in 2015.GSK also sued Pfizer for patent infringement last year over technology used in Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo. Pfizer has denied GSK's claims in that case.","news_type":1},"isVote":1,"tweetType":1,"viewCount":30,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":30,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}